Biomark Diagnostics
2007
FOUNDED
PUBLIC
STATUS
BUX
STOCK SYMBOL
$0.07
SHARE PRICE
(As of Wednesday Closing)
Description
Developer of advanced stage diagnostic technologies intended to increase the accuracy of cancer diagnostics. The company's advanced stage diagnostic technologies consists of screening for the acetylated form of a drug (Amantadine) given to patients prior to measurement via LC MS in body fluids, this acetylation is performed by the enzyme, spermine/spermidine n-acetyl transferase (SSAT), enabling medical institutions to gain universal access to effective cancer diagnostic tools.
Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Healthcare Technology Systems
Stock Exchange
CNQ
Primary Office
- 165 - 10551 Shellbridge Way
- Richmond, British Columbia V6X 2W8
- Canada
+1 (604) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Biomark Diagnostics’s full profile, request a free trial.
Biomark Diagnostics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $0.05 - $0.13 | $4.91M | $0.08 | 25.6K | 62.8M |
Biomark Diagnostics Financials Summary
|
In Thousands,
USD |
TTM
31-Dec-2017
|
FY 2017
31-Mar-2017
|
FY 2016
31-Mar-2016
|
FY 2015
31-Mar-2015
|
|---|---|---|---|---|
| Enterprise Value | 4,675 | 3,865 | 5,948 | 14,998 |
| EBITDA | (629) | (545) | (1,068) | (2,525) |
| Net Income | (629) | (545) | (1,068) | (2,525) |
| Total Assets | 117 | 30 | 26 | 182 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Biomark Diagnostics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Biomark Diagnostics‘s full profile, request access.
Request full access to PitchBook